Ono, BMS Sue Merck Over Newly Approved Keytruda Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Ono Pharmaceutical and its co-developer Bristol-Myers Squibb filed a U.S. suit against Merck, accusing it of violating their patent.